The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that Cour Pharmaceuticals is developing to reprogram the immune system in generalized myasthenia […] The post FDA grants orphan drug designation to CNP-106 for gMG appeared first on Myasthenia Gravis News.
